Larimar Therapeutics

Larimar Reports Promising Friedreich’s Ataxia Data as Nomlabofusp Nears Phase 3 Launch

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced third-quarter 2025 financial results and a clinical update highlighting continued progress in its nomlabofusp development program for Friedreich’s ataxia (FA), …

Larimar Reports Promising Friedreich’s Ataxia Data as Nomlabofusp Nears Phase 3 Launch Read More